Company Description
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform.
In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 4, 2018 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,021 |
| CEO | Dr. Helmy Eltoukhy Ph.D. |
Contact Details
Address: 3100 Hanover Street Palo Alto, California 94304 United States | |
| Phone | 855 698 8887 |
| Website | guardanthealth.com |
Stock Details
| Ticker Symbol | GH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001576280 |
| CUSIP Number | 40131M109 |
| ISIN Number | US40131M1099 |
| Employer ID | 45-4139254 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. AmirAli Talasaz Ph.D. | Co-Chief Executive Officer and Director |
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-Chief Executive Officer and Chairman |
| Michael Bell | Chief Financial Officer |
| Darya Chudova | Chief Technology Officer |
| Dr. Craig Eagle M.D. | Chief Medical Officer |
| Christopher Freeman | Chief Commercial Officer |
| Kumud Kalia | Chief Information Officer |
| Zarak Khurshid | Vice President of Investor Relations |
| John G. Saia J.D. | Chief Legal Officer and Corporate Secretary |
| Jennifer Higgins | Senior Vice President of Public Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2025 | 144 | Filing |
| Feb 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 20, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 144 | Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | 8-K | Current Report |
| Jan 17, 2025 | 144 | Filing |